EUCTR2009-015336-15-IT进行中（未招募）不适用
ong-term treatment for cancer patients with deep venous thrombosis or pulmonary embolism - ND
IVERSITA` DEGLI STUDI G. D`ANNUNZIO CHIETI0 个研究点目标入组 1,000 人开始时间: 2010年4月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with cancer and confirmed pulmonary embolism or deep vein thrombosis who have been treated for 6 to 12 months with therapeutic doses of low molecular weight heparin, vitamin K antagonist or a new anticoagulant in a trial 2. Indication for long-term anticoagulant therapy (e.g. because of metastasized disease or chemotherapy) 3 Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Legal age limitations (country specific) 2. Indications for anticoagulant therapy other than deep vein thrombosis or pulmonary embolism 3. Any contraindication listed in the local labeling of low molecular weight heparins, warfarin or vitasmin K antagonists 4. Childbearing potential without proper contraceptive measures, pregnancy or breastfeeding 5. Life expectancy <3 months
研究者
相似试验
进行中（未招募）
不适用
ong-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized open label studyEUCTR2009-015336-15-DEDepartment of Vascular Medicine of the Academic Medical Center1,000
进行中（未招募）
不适用
ong-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized open label studyDeep venous thrombosis or pulmonary embolism in patients with cancerMedDRA version: 12.0Level: LLTClassification code 10066899Term: Venous thromboembolismEUCTR2009-015336-15-NLDepartment of Vascular Medicine of the Academic Medical Center1,000
尚未招募
不适用
ong-term treatment of deep vein thrombosis or pulmonary embolism in patients with cancerpulmonary embolismdeep vein thrombosisvenous thromboembolismcancerkankerlongemboliediep veneuze tromboseveneuze trombo-embolieNL-OMON28644niversity Medical Center Groningen200
进行中（未招募）
1 期
ong-term treatment of cancer associated VTE: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated ThrombosisPatients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of anticoagulant therapy for the treatment of the index event, with no objectively documented symptomatic recurrence of VTE between the index event and randomization.MedDRA version: 20.0Level: LLTClassification code 10076654Term: Cancer-associated thrombosisSystem Organ Class: 100000004864EUCTR2017-003342-25-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)1,722
进行中（未招募）
1 期
ong-term treatment of cancer associated VTE: reduced vs full dose of apixaban : API-CAT STUDY for APIxaban Cancer Associated ThrombosisAny cancer diagnosed histologically (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intra-cerebral metastasis, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, afterat least 6 months of anticoagulant therapy for the treatment of the index event, with no objectively documented symptomatic recurrence of VTE between the index event and randomization.MedDRA version: 21.1Level: LLTClassification code 10076654Term: Cancer-associated thrombosisSystem Organ Class: 100000004864EUCTR2017-003342-25-GRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)1,722